New drug application: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (2 revisions) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
A new drug application (NDA) is an application submitted by the manufacturer of a drug to the FDA - after [[clinical trials]] have been completed - for a license to market the drug for a specified indication. | A new drug application (NDA) is an application submitted by the manufacturer of a drug to the FDA - after [[clinical trials]] have been completed - for a license to market the drug for a specified indication. | ||
[[Category:Jargon]] | |||
Latest revision as of 20:31, 8 October 2012
A new drug application (NDA) is an application submitted by the manufacturer of a drug to the FDA - after clinical trials have been completed - for a license to market the drug for a specified indication.